Early referral strategies for management of people with markers of renal disease: A systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis

Health Technology Assessment

Volumn 14, Issue 21, 2010, Pages 1-184

  Black, C ^a   Sharma, P ^a   Scotland, G ^a   McCullough, K ^b   McGurn, D ^a   Robertson, L ^a   Fluck, N ^b   MacLeod, A ^b   McNamee, P ^a   Prescott, G ^a   Smith, C ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NHS GRAMPIAN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PLACEBO; SERUM ALBUMIN;

AGE; ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CONSULTATION; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DEPRESSION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIALYSIS; DISEASE COURSE; DRUG COST; ECONOMIC EVALUATION; GLOMERULUS FILTRATION RATE; HEALTH CARE ACCESS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; MACROALBUMINURIA; MICROALBUMINURIA; MORTALITY; NEPHROLOGIST; PATIENT ATTITUDE; PATIENT EDUCATION; PATIENT REFERRAL; PHYSICIAN ATTITUDE; PRIMARY MEDICAL CARE; PROTEIN RESTRICTION; PROTEINURIA; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RACE; RENAL REPLACEMENT THERAPY; RISK REDUCTION; SEX DIFFERENCE; SMOKING; SYSTEMATIC REVIEW;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; CREATININE; DISEASE PROGRESSION; EARLY DIAGNOSIS; EVIDENCE-BASED PRACTICE; GREAT BRITAIN; HUMANS; KIDNEY FUNCTION TESTS; MARKOV CHAINS; MODELS, ECONOMETRIC; MODELS, ORGANIZATIONAL; NEPHROLOGY; OUTCOME ASSESSMENT (HEALTH CARE); REFERRAL AND CONSULTATION; RENAL INSUFFICIENCY, CHRONIC; RESEARCH DESIGN;

EID: 77952374233     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta14210     Document Type: Article

References (369)

1. Department of Health. Second progress report on the renal NSF. 2007. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_074811 (accessed May 2009).
2. Department of Health. National Service Framework for Renal Services - Part Two: Chronic kidney disease, acute renal failure and end of life care. 2005. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4101902 (accessed June 2009).
3. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
4. McGregor SM. How common is early chronic kidney disease? A background paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease. Nephrol Dial Transplant 2007;22:ix8-ix18.
5. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005;20:2587-93.
6. Ansell D, Feehally J, Fogarty D, Ford D, Hodsman A, Tomson C, et al. UK Renal Registry: The eleventh annual report. 2008. URL: www.renalreg.com/Reports/2008.html (accessed May 2009).
7. Ansell D, Roderick P, Hodsman A, Ford D, Stennkamp R, Tomson C. Survival and causes of death of UK adult patients on Renal Replacement Therapy in 2007: national and centre-specific analyses. The UK Renal Registry: The Eleventh Annual Report. 2008. URL: www.renalreg.com/reports/renal-registryreports/2008/ (accessed May 2009).
8. Merkus MP, Jager KJ, Dekker FW, Boeschoten EW, Stevens P, Krediet RT. Quality of life in patients on chronic dialysis: self-assessment 3 months after the start of treatment. The Necosad Study Group. Am J Kidney Dis 1997;29:584-92.
9. Evans RW, Manninen DL, Garrison LP, Hart LG, Blagg CR, Gutman RA, et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985;312:553-9.
10. Department of Health. National Service Framework for Renal Services: Part One - Dialysis and transplantation. 2004. URL: www.dh.gov.uk/en/Publicationsandstatistics/PublicationsPolicyAndGuidance/DH_4070359 (accessed June 2009).
11. National Institute for Health and Clinical Excellence. Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure. 2002. URL: http://guidance.nice.org.uk/TA48 (accessed May 2009).
12. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function - Measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-83.
13. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998;32:992-9.
14. Wesson LG. Physiology of the human kidney. New York, NY: Grune & Straton, 1969.
15. Couchoud C, Pozet N, Labeeuw M, PouteilNoble C. Screening early renal failure: Cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int 1999;55:1878-84.
16. Lamb EJ, Tomson CRV, Roderick PJ. Estimating kidney function in adults using formulae. Ann Clin Biochem 2005;42:321-45.
17. Snyder S, Pendergraph B. Detection and evaluation of chronic kidney disease. Am Fam Physician 2005;72:1723-32.
18. Traynor J, Mactier R, Geddes CC, Fox JG. How to measure renal function in clinical practice. BMJ 2006;333:733-7.
19. Levey AS, Schoolwerth AC, Burrows NR, Williams DE, Stith KR, McClennan W. Comprehensive public health strategies for preventing the development, progression, and complication of CKD: Report of an Expert Panel Convened by Centers for Disease Control and Prevention. Am J Kidney Dis 2009;53:522-35.
20. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Int Med 2003;139:137-47.
21. Levey AS, Eckardt K-U, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089-100.
22. The Renal Association. Consensus statement on management of early CKD, February 2007. 2007. URL: www.renal.org/CKDguide/consensus.html (accessed April 2009).
23. National Institute for Health and Clinical Excellence. Early identification and management of chronic kidney disease in adults in primary and secondary care. 2008. URL: http://guidance.nice.org.uk/CG73 (accessed March 2009).
24. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007;72:247-59.
25. Levin A. The advantage of a uniform terminology and staging system for chronic kidney disease (CKD). Nephrol Dial Transplant 2003;18:1446-51.
26. Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, Chianchiano D, McClellan WM, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis 2006;3:A57.
27. Saydah S, Eberhardt M, Rios-Burrows N, Williams D, Geiss L, Dorsey R. Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004. JAMA 2007;297:1767-8.
28. Castro AF, Coresh J. CKD surveillance using laboratory data from the population-based National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009;53:S46-S55.
29. Coresh J, Stevens AL, Levey AS. Chronic kidney disease is common: What do we do next? Nephrol Dial Transplant 2008;23:1122-5.
30. Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 2005;16:180-8.
31. Iseki K, Kinjo K, Iseki C, Takishita S. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 2004;44:806-14.
32. Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, et al. Screening strategies for chronic kidney disease in the general population: Follow-up of cross sectional health survey. BMJ 2006;333:1047-50.
33. Cirillo M, Laurenzi M, Mancini M, Zanchetti A, Lombardi C, De Santo NG. Low glomerular filtration in the population: Prevalence, associated disorders, and awareness. Kidney Int 2006;70:800-6.
34. Nitsch D, Dietrich DF, von Eckardstein A, Gaspoz JM, Downs SH, Leuenberger P. Prevalence of renal impairment and its association with cardiovascular risk factors in a general population: results of the Swiss SAPALDIA study. Nephrol Dial Transplant 2006;21:935-44.
35. Otero A, Gayoso P, Garcia F, de Francisco AL, on behalf of the EPIRCE study group. Epidemiology of chronic renal disease in the Galician population: results of the pilot Spanish EPIRCE study. Kidney Int Suppl 2005;99:S16-19.
36. Viktorsdottir O, Palsson R, Andresdottir MB, Aspelund T, Gudnason V, Indridason OS. Prevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria in Icelandic adults. Nephrol Dial Transplant 2005;20:1799-807.
37. Wannamethee SG, Shaper AG, Lowe GD, Lennon L, Rumley A, Whincup PH. Renal function and cardiovascular mortality in elderly men: the role of inflammatory, procoagulant, and endothelial biomarkers. Eur Heart J 2006;27:2975-81.
38. de LS, Chan T, Stevens P, O'Donoghue D, Hague N, Dzregah B, et al. Identifying patients with chronic kidney disease from general practice computer records. Fam Pract 2005;22:234-41.
39. Ali T, Black C, Prescott G, MacLeod A, Simpson C, Khan I, et al. Preventing end stage renal disease: informing the development of a public health strategy. Chief Scientist Office - Research in Focus. 2007. URL: www.sehd.scot.nhs.uk/cso/Publications/ExecSumms/OctNov07/Ali.pdf (accessed July 2008).
40. The Renal Association. The UK CKD Guidelines (2005). 2005. URL: www.renal.org/CKDguide/ckd2005.html (accessed May 2009).
41. Lamb EJ. United Kingdom guidelines for chronic kidney disease. Scand J Clin Lab Invest Suppl 2008;241:16-22.
42. Scottish Intercollegiate Guidelines Network. Diagnosis and management of chronic kidney disease. 2008. URL: www.sign.ac.uk/guidelines/fulltext/103/index.html (accessed December 2008).
43. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Int Med 2001;135:73-87.
44. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006;4:CD006257.
45. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000;35:695-707.
46. Siebenhofer A, Plank J, Horvath K, Berghold A, Sutton AJ, Sommer R, et al. Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials. Diabet Med 2004;21:18-25.
47. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-33.
48. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336:645-51.
49. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17:2006-16.
50. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 2001;59:260-9.
51. Fouque D, Laville M, Boissel JP. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev 2006;2:CD001892.
52. Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev 2007;4:CD002181.
53. Zarazaga A, Garcia-De-Lorenzo L, Garcia-Luna PP, Garcia-Peris P, Lopez-Martinez J, Lorenzo V, et al. Nutritional support in chronic renal failure: systematic review. Clinical Nutrition 2001;20:291-9.
54. Lameire N, Van BW. The pattern of referral of patients with end-stage renal disease to the nephrologist--a European survey. Nephrol Dial Transplant 1999;14(Suppl. 6):16-23.
55. Nakamura S. N. Effect of early nephrology referral on the initiation of hemodialysis and survival in patients with chronic kidney disease and cardiovascular diseases. Circ J 2007;71:511-16.
56. Roderick P, Jones C, Drey N, Blakeley S, Webster P, Goddard J, et al. Late referral for end-stage renal disease: a region-wide survey in the south west of England. Nephrol Dial Transplant 2002;17:1252-9.
57. Chan MR, Dall AT, Fletcher KE, Lu N, Trivedi H. Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. Am J Med 2007;120:1063-70.
58. Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. 2001. URL: www.york.ac.uk/inst/crd/report4.htm (accessed March 2008).
59. National Institute for Health and Clinical Excellence. The guidelines manual 2007 - all chapters. 2007. URL: www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/clinicalguidelinedevelopmentmethods/theguidelinesmanual2007/the_guidelines_manual_2007.jsp (accessed March 2008).
60. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes. 2008. URL: www.nice.org.uk/Guidance/CG66 (accessed May 2008).
61. Drummond FM, Jefferson OT. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
62. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8(36).
63. National Institute of Clinical Excellence. The guidelines manual-Appendix B: Methodology checklist: Systematic reviews and meta- analyses. 2007. URL: www.nice.org.uk/niceMedia/pdf/GuidelinesmanualAppendixB.pdf (accessed 30 March 2008).
64. Critical Appraisal Skills Pragramme. 12 questions to help you make a sense of cohort study. Public health resource unit. 2004. URL: www.phru.nhs.uk/Pages/PHD/resources.htm (accessed 26 March 2008).
65. Sanderson S, Tatt ID, Higgins J. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007;36:666.
66. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377-84.
67. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in metaanalyses. 2008. URL: www.ohri.ca/programs/clinical_epidemiology/oxford.htm (accessed March 2008).
68. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 2006;17:2034-47.
69. Di AE, Danesh J, Eiriksdottir G, Gudnason V. Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med 2007;4:e270.
70. Muntner P, He J, Hamm L, Loria C, Whelton P. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002;13:745-53.
71. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem D, Griffith J, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41:48-55.
72. Manjunath G, Tighiouart H, Coresh J, MacLeod B, Salem D, Griffith J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003;63:1121-9.
73. Culleton BF, Larson MG, Wilson PWF, Evan JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-19.
74. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004;15:1307-15.
75. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296.
76. Meisinger C, Doring A, Lowel H. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J 2006;27:1245-50.
77. Dale PL, Hutton J, Elgazzar H. Utility of health states in chronic kidney disease: a structured review of the literature. Curr Med Res Opin 2008;24:193-205.
78. Gorodetskaya I, Zenios S, McCulloch CE, Bostrom A, Hsu CY, Bindman AB, et al. Healthrelated quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005;68:2801-8.
79. Bruno G, Merletti F, Bargero G, Novelli G, Melis D, Soddu A, et al. Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. Diabetologia 2007;50:941-8.
80. Patel UD, Young EW, Ojo AO, Hayward RA. CKD progression and mortality among older patients with diabetes. Am J Kidney Dis 2005;46:406-14.
81. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006;69:1264-71.
82. Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, et al. Slower decline of glomerular filtration rate in the Japanese general population: A longitudinal 10-year follow-up study. Hypertens Res 2008;31:433-41.
83. Djamali A, Kendziorski C, Brazy PC, Becker BN. Disease progression and outcomes in chronic kidney disease and renal transplantation. Kidney Int 2003;64:1800-7.
84. Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J, et al. Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter. Am J Kidney Dis 2001;38:1398-407.
85. Astor BC, Hallan SI, Miller ER, III, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008;167:1226-34.
86. Maaravi Y, Bursztyn M, Hammerman-Rozenberg R, Stessman J. Glomerular filtration rate estimation and mortality in an elderly population. QJM 2007;100:441-9.
87. Mulec H, Blohme G, Grande B, Bjorck S. The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. Nephrol Dial Transplant 1998;13:651-5.
88. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004;66:1596-605.
89. Tarnow L, Hildebrandt P, Hansen BV, BorchJohnsen K, Parving H-H. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia 2005;48:149-55.
90. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F, MMKD Study G. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int 2007;71:1279-86.
91. Cvengros JA, Christensen AJ, Lawton WJ. Health locus of control and depression in chronic kidney disease: a dynamic perspective. J Health Psychol 2005;10:677-86.
92. Herzog CA, Muster HA, Li S, Collins AJ. Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. J Card Fail 2004;10:467-72.
93. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int 2001;59:702-9.
94. Tseng C-L, Kern EFO, Miller DR, Tiwari A, Maney M, Rajan M, et al. Survival benefit of nephrologic care in patients with diabetes mellitus and chronic kidney disease. Arch Intern Med 2008;168:55-62.
95. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis 2003;42:677-84.
96. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int 2006;69:375-82.
97. Eriksen BO, Ingebretsen OC. In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression. Kidney Int 2007;72:1242-8.
98. Evans M, Fryzek JP, Elinder CG, Cohen SS, McLaughlin JK, Nyren O, et al. The natural history of chronic renal failure: results from an unselected, population-based, inception cohort in Sweden. Am J Kidney Dis 2005;46:863-70.
99. Hallan S, Astor B, Romundstad S, Aasarod K, Kvenild K, Coresh J. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals. Arch Intern Med 2007;167:2490-6.
100. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009;20:1069-77.
101. Hemmelgarn BR, Zhang J, Manns BJ, Tonelli M, Larsen E, Ghali WA, et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int 2006;69:2155-61.
102. Hovind P, Tarnow L, Rossing P, Teerlink T, Stehouwer CD, Emeis JJ, et al. Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1. Am J Kidney Dis 2001;38:1376-80.
103. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 2003;14:2902-7.
104. John R, Webb M, Young A, Stevens PE. Unreferred chronic kidney disease: a longitudinal study. Am J Kidney Dis 2004;43:825-35.
105. Jones C, Roderick P, Harris S, Rogerson M. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant 2006;21:2133-43.
106. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-63.
107. Gullion CM, Keith DS, Nichols GA, Smith DH. Impact of comorbidities on mortality in managed care patients with CKD. Am J Kidney Dis 2006;48:212-20.
108. Khatami Z, Handley G, Narayanan K, Weaver JU. Applicability of estimated glomerular filtration rate in stratifying chronic kidney disease. Scand J Clin Lab Invest 2007;67:297-305.
109. Leehey DJ, Kramer HJ, Daoud TM, Chatha MP, Isreb MA. Progression of kidney disease in type 2 diabetes - Beyond blood pressure control: An observational study. BMC Nephrol 2005;6:8.
110. O'Hare AM, Bertenthal D, Covinsky KE, Landefeld CS, Sen S, Mehta K, et al. Mortality risk stratification in chronic kidney disease: One size for all ages? J Am Soc Nephrol 2006;17:846-53.
111. Orlando LA, Owen WF, Matchar DB. Relationship between nephrologist care and progression of chronic kidney disease. N C Med J 2007;68:9-16.
112. Coresh J, Astor BC, McQuillan G, Kusek J, Greene T, Van Lente F, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002;39:920-9.
113. Murthy K, Stevens LA, Stark PC, Levey AS. Variation in the serum creatinine assay calibration: A practical application to glomerular filtration rate estimation. Kidney Int 2005;68:1884.
114. Garg AX, Clark WF, Haynes B, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I. Kidney Int 2002;61:1486-94.
115. Sihvonen S, Korepelaa M, Mustonen J, Laippala P, Pasternack A. Renal disease as a predictor of increased mortality among patients with rheumatoid arthritis. Nephron 2004;96:107-14.
116. Chow FYF, Briganti EM, Kerr PG, Chadban SJ, Zimmet PZ, Atkins RC. Health-related quality of life in Australian adults with renal insufficiency: a population-based study. Am J Kidney Dis 2003;41:596-604.
117. van der Velde M, Halbesma N, de Charro FT, Bakker SJL, de Zeuw D, de Jong PE, et al. Screening for albuminuria identifies individuals at increased renal risk. J Am Soc Nephrol 2009;20:852-62.
118. Fried L. Are we ready to screen the general population for microalbuminuria? J Am Soc Nephrol 2009;20:686-8.
119. Kessler M, Frimat L, Panescu V, Briancon S. Impact of nephrology referral on early and midterm outcomes in ESRD: EPidemiologie de l'Insuffisance REnale chronique terminale en Lorraine (EPIREL): results of a 2-year, prospective, community-based study. Am J Kidney Dis 2003;42:474-85.
120. Martinez-Ramirez HR, Jalomo-Martinez B, Cortes-Sanabria L, Rojas-Campos E, Barragan G, Alfaro G, et al. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist. Am J Kidney Dis 2006;47:78-87.
121. Jungers P, Massy ZA, Nguyen-Khoa T, Choukroun G, Robino C, Fakhouri F, et al. Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients. Nephrol Dial Transplant 2001;16:2357-64.
122. Khan SS, Xue JL, Kazmi WH, Gilbertson DT, Obrador GT, Pereira BJG, et al. Does predialysis nephrology care influence patient survival after initiation of dialysis? Kidney Int 2005;67:1038-46.
123. Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Int Med 2002;137:479.
124. Khan IH, Catto GR, Edward N, MacLeod AM. Chronic renal failure: factors influencing nephrology referral. QJM 1994;87:559-64.
125. Himmelfarb J. Chronic kidney disease and the public health: gaps in evidence from interventional trials. JAMA 2007;297:2630-3.
126. The Renal Association. A vision for the future of renal services. 2002. URL: www.renal.org/Statements/NSFsub.html (accessed October 2008).
127. Blendon RJ, Schoen C, DesRoches C, Osborn R, Zapert K. Common concerns amid diverse systems: health care experiences in five countries. Health Aff 2003;22:106-21.
128. Epping-Jordan JE, Pruitt SD, Bengoa R, Wagner EH. Improving the quality of health care for chronic conditions. Qual Saf Health Care 2004;13:299-305.
129. Deakin T, McShane CE, Cade JE, Williams RD. Group based training for self-management strategies in people with type 2 diabetes mellitus. Evid Based Nurs 2005;8:111.
130. Norris SL, Nichols PJ, Caspersen CJ, Glasgow RE, Engelgau MM, Jack L, et al. The effectiveness of disease and case management for people with diabetes. A systematic review. Am J Prev Med 2002;22:(Suppl. 38).
131. Renders CM, Valk GD, Griffin SJ, Wagner EH, Eijk Van JT, Assendelft WJ. Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review. Diabetes Care 2001;24:1821-33.
132. Goeddeke-Merickel CM. The goals of comprehensive and integrated disease state management for diabetic kidney disease patients. Adv Chronic Kidney Dis 2005;12:236-42.
133. Ifudu O, Friedman EA. Managing chronic renal insufficiency--intertwined roles of non-nephrologist and nephrologist. J Natl Med Assoc 2003;95:43-54.
134. Leung WY, So WY, Tong PC, Lo MK, Lee KF, Ko GT, et al. The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy. Nephrol Dial Transplant 2004;19:2519-25.
135. Ahmad A, Roderick P, Ward M, Steenkamp R, Burden R, O'Donoghue D, et al. Current chronic kidney disease practice patterns in the UK: a national survey. QJM 2006;99:245-51.
136. Jones C, Roderick P, Rogerson M. A national survey of shared care schemes for managing chronic kidney disease. BRS Conference Programme. 2004.
137. Minutolo R, De NL, Zamboli P, Chiodini P, Signoriello G, Toderico C, et al. Management of hypertension in patients with CKD: differences between primary and tertiary care settings. Am J Kidney Dis 2005;46:18-25.
138. Minutolo R, Sasso FC, Chiodini P, Cianciaruso B, Carbonara O, Zamboli P, et al. Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings. J Hypertens 2006;24:1655-61.
139. Locatelli F, Zoccali C, SIR SIN Study Investigators. Clinical policies on the management of chronic kidney disease patients in Italy. Nephrol Dial Transplant 2008;23:621-6.
140. Hobbs H, Irving J, Farmer C, Jenkins K, John I. The impact of eGFR implementation on clinical practice: Finding solutions through a CKD network. BRS/RA Conference, Abstract book 2008. p. 206.
141. Cortes-Sanabria L, Cabrera-Pivaral CE, CuetoManzano AM, Rojas-Campos E, Barragan G, Hernandez-Anaya M, et al. Improving care of patients with diabetes and CKD: a pilot study for a cluster-randomized trial. Am J Kidney Dis 2008;51:777-88.
142. Curtis BM, Ravani P, Malberti F, Kennett F, Taylor PA, Djurdjev O, et al. The short- and longterm impact of multi-disciplinary clinics in addition to standard nephrology care on patient outcomes. Nephrol Dial Transplant 2005;20:147-54.
143. Hardy KJ, Furlong NJ, Hulme SA, O'Brien SV. Delivering improved management and outcomes in diabetic kidney disease in routine clinical care. Br J Diabetes Vasc Dis 2007;7:172-8.
144. Harnett P, Grigoriou A, Mapplebeck S, Almond M. Virtual CKD clinic provides equivalent surveillance when compared to primary care. BRS/RA Conference, Abstract book 2008. p. 218.
145. Harris LE, Luft FC, Rudy DW, Kesterson JG, Tierney WM. Effects of multidisciplinary case management in patients with chronic renal insufficiency. Am J Med 1998;105:464-71.
146. Hemmelgarn BR, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Walsh M, et al. Association between multidisciplinary care and survival for elderly patients with chronic kidney disease. J Am Soc Nephrol 2007;18:993-9.
147. Jones C, Roderick P, Harris S, Rogerson M. An evaluation of a shared primary and secondary care nephrology service for managing patients with moderate to advanced CKD. Am J Kidney Dis 2006;47:103-14.
148. Kelly CJG, Booth G. Pharmacist-led structured care for patients with diabetic nephropathy. Br J Diabetes Vasc Dis 2008;8:86-8.
149. Leung WY, So WY, Tong PC, Chan NN, Chan JC. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy. Am J Med 2005;118:1414.
150. Richards N, Harris K, Whitfield M, O'Donoghue D, Lewis R, Mansell M, et al. Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes. Nephrol Dial Transplant 2008;23:549-55.
151. Thanamayooran S. R. Effectiveness of a multidisciplinary kidney disease clinic in achieving treatment guideline targets. Nephrol Dial Transplant 2005;20:2385-93.
152. Bending J, Kingswood C. Joint diabetes renal clinics are 'best practice'. Br J Diabetes Vasc Dis 2007;7:202.
153. Compton A, Provenzano R, Johnson CA. The nephrology nurse's role in improved care of patients with chronic kidney disease. Nephrol Nurs J 2002;29:331-6.
154. Ghossein C, Serrano A, Rammohan M, Batlle D. The role of comprehensive renal clinic in chronic kidney disease stabilization and management: The Northwestern experience. Semin Nephrol 2002;22:526-32.
155. Hostetter TH, Lising M. National kidney disease education program. J Am Soc Nephrol 2003;14:S114-S116.
156. Joy MS, DeHart RM, Gilmartin C, Hachey DM, Hudson JQ, Pruchnicki M, et al. Clinical pharmacists as multidisciplinary health care providers in the management of CKD: A joint opinion by the nephrology and ambulatory care practice and research networks of the American College of Clinical Pharmacy. Am J Kidney Dis 2005;45:1105-18.
157. Thomas N. Collaboration between hospital and primary care can improve the management of diabetic nephropathy. Br J Diabetes Vasc Dis 2004;4:202-4.
158. Thomas N. Can we delay the progression of chronic kidney disease (CKD) by improving collaboration between renal units and primary care teams? EDTNA ERCA J 2005;31:178-81.
159. Mendelssohn DC, Toffelmire EB, Levin A. Attitudes of Canadian nephrologists toward multidisciplinary team-based CKD clinic care. Am J Kidney Dis 2006;47:277-84.
160. Anon. Combating chronic kidney disease: A managed care perspective. Am J Manag Care 2002;8:S112-S113.
161. Anon. PCPs need to step up their care of patients with CKD. Dis Manag Advis 2007;13:13-15.
162. Levin A. The need for optimal and coordinated management of CKD. Kidney Int Suppl 2005;S7-10.
163. St Peter WL, Schoolwerth AC, McGowan T, McClellan WM. Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomes. Am J Kidney Dis 2003;41:903-24.
164. Curtin RB, Becker B, Kimmel PL, Schatell D. An integrated approach to care for patients with chronic kidney disease. Seminars in Dialysis 2003;16:399-402.
165. Mendelssohn DC. Coping with the CKD epidemic: the promise of multidisciplinary team-based care. [comment]. Nephrol Dial Transplant 2005;20:10-12.
166. Chen RA, Scott S, Mattern WD, Mohini R, Nissenson AR. The case for disease management in chronic kidney disease. Dis Manag 2006;9:86-92.
167. Kirby R. Multidisciplinary care for kidney disease patients. Nat Clin Pract Nephrol 2006;2:10.
168. Tomlinson J. How do we re-design the treatment? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrol Dial Transplant 2007;22(Suppl. 9):ix39-44.
169. Komenda P, Levin A. Analysis of cardiovascular disease and kidney outcomes in multidisciplinary chronic kidney disease clinics: complex disease requires complex care models. Curr Opin Nephrol Hypertens 2006;15:61-6.
170. Spry L. Building the chronic kidney disease management team. Adv Chron Kidney Dis 2008;15:29-36.
171. Frankel A, Brown E, Wingfield D. Management of chronic kidney disease. BMJ 2005;330:1039-40.
172. Rutecki GW. Putting guidelines for chronic kidney disease into practice. Consultant 2006;46:1295.
173. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes (update). 2008. URL: www.nice.org.uk/guidance/index.jsp?action=byID&o=11983 (accessed December 2008).
174. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
175. Heffernan C. Screening for chronic kidney disease: an evidence based review for the national screening committe. 2008. URL: www.screening.nhs.uk/ckd (accessed June 2009).
176. NHS Scotland. Keep Well Scotland. 2009. URL: www.keepwellscotland.com/ (accessed 24 September 2009).
177. Department of Health. Improving chronic disease management. 2004. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4075214 (accessed May 2009).
178. Atthobari J, Asselbergs FW, Boersma C, de VR, Hillege HL, van Gilst WH, et al. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clin Ther 2006;28:432-44.
179. Boulware LE, Jaar BG, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. J Am Med Assoc 2003;290:3101-14.
180. McLaughlin K, Manns B, Culleton B, Donaldson C, Taub K. An economic evaluation of early versus late referral of patients with progressive renal insufficiency. Am J Kidney Dis 2001;38:1122-8.
181. Binik YM, Devins GM, Barre PE, Guttmann RD, Hollomby DJ, Mandin H, et al. Live and learn: patient education delays the need to initiate renal replacement therapy in end-stage renal disease. J Nerv Ment Dis 1993;181:371-6.
182. Asselbergs FW, Diercks GF, Hillege HL, Van Boven AJ, Janssen WM, Voors AA, et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVENT IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110:2809-16.
183. Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. To pay or not to pay? A decision and cost utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. CMAJ 2000;162:195-8.
184. Stafylas PC, Sarafidis PA, Grekas DM, Lasaridis AN. A cost-effectiveness analysis of angiotensinconverting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy. J Clin Hypertens 2007;9:751-9.
185. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick A, Vijan S. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Int Med 2005;143:89-99.
186. Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordinnier DJ. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy; costeffectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol Dial Transplant 2003;18:2059-66.
187. Palmer AJ, Tucker D.M., Valentine WJ, Roze S, Gabriel S, Cordonnier DJ. Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrol Dial Transplant 2005;20:1103-9.
188. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001;357:1601-8.
189. van Hout BA, Simeon GP, McDonnell J, Mann JF. Economic evaluation of benazepril in chronic renal insufficiency. Kidney Int Suppl 1997;63:59-62.
190. Howard K, Salkeld G, White S, Chadban S, Craig J, McDonald S, et al. The cost-effectiveness of early detection and intervention to prevent the progression of chronic kidney disease in Australia. 2006. URL: www.kidney.org.au/ (accessed 2009).
191. Khan S, Amedia CA. Economic burden of chronic kidney disease. J Eval Clin Pract 2008;14:422-34.
192. Stevens PE, O'Donoghue DJ, de LS, Van VJ, Klebe B, Middleton R, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 2007;72:92-9.
193. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. J Am Med Assoc 2007;298:2038-47.
194. Parikh NI, Hwang SJ, Larson MG, Levy D, Fox CS. Chronic kidney disease as a predictor of cardiovascular disease (from the Framingham Heart Study). Am J Cardiol 2008;102:47-53.
195. Foster MC, Hwang SJ, Larson MG, Parikh NI, Meigs J.B., Vasan RS, et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med 2007;167:1386-92.
196. Weiner DE, Tabatabai S, Elsayed E, Bansal N, Griffith J, Salem DN, et al. Cardiovascular outcomes and all cause mortality: Exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 2006;48:392-401.
197. Lorber D, Reddan D. Clinical characteristics of chronic kidney disease patients with and without diabetes: a subanalysis of the PAERI study. Clin Nephrol 2006;66:11-16.
198. Gerstein HC, Mann JF, Pogue J, Dinneen SF, Halle JP, Hoogwerf B, et al. Prevalence and determinants of microalbuminuria in highrisk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care 2000;23:B35-B39.
199. Welcome to the QRISK® 2 cardiovascular disease risk calculator. 2009. URL: http://qr2.dyndns.org/ (accessed April 2009).
200. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82.
201. Heart Protection Study Collaborative. Lifetime costeffectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ 2006;333:1145-9.
202. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997;51:1908-19.
203. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32.
204. Office of National Statistics. Mid-2005 population estimates: England and Wales; estimated resident population by single year of age and sex. 2006. URL: www.statistics.gov.uk/statbase/ssdataset.asp?vlnk=9389&More=Y (accessed February 2009).
205. Office of National Statistics. Death by age, sex and underlying cause, 2005 registrations: Health statistics quarterly 30. 2006. URL: www.statistics.gov.uk/StatBase/ssdataset.asp?vlnk=9346&Pos=&ColRank=272 (accessed February 2009)
206. McManus RJ, Mant J, Roalfe A, Oakes RA, Bryan S, Pattison HM, et al. Targets and self monitoring in hypertension: randomised controlled trial and cost effectiveness analysis. Br Med J 2005;331:493.
207. Baboolal K, McEwan P, Sondhi S, Spiewanowski P, Wechowski J, Wilson K. The cost of renal dialysis in a UK setting - a multicentre study. Nephrol Dial Transplant 2008;23:1982-9.
208. Department of Health. NHS reference costs 2006-07. 2008. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082571 (accessed February 2009).
209. Curtis L. Unit costs of health and social care 2007. Personal Social Service Research Unit (PSSRU). 2008. URL: www.pssru.ac.uk/uc/uc2007contents.htm (accessed February 2009).
210. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 56. London: BMA and RPS; 2008.
211. National Institute for Health and Clinical Excellence. Chronic kidney disease costing report: Implementing NICE guidance. 2008. URL: www.nice.org.uk/nicemedia/pdf/CG73CostingReport.PDF (accessed September 2009).
212. Burden R, Tomson C. Identification, management and referral of adults with chronic kidney disease: Concise guidelines. Clin Med 2005;5:635-42.
213. Menon V, Wang X, Sarnak MJ, Hunsicker LH, Madero M, Beck GJ, et al. Long-term outcomes in nondiabetic chronic kidney disease. Kidney Int 2008;73:1310-15.
214. Wakai K, Kawamura T, Endoh M, Kojima M, Tomino Y, Tamakoshi A, et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant 2006;21:2800-8.
215. Burnier M, Zanchi A. Blockage of the reninangiotensinaldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006;24:11-25.
216. Palmer AJ, Annemans L, Roze S, Lapuerta P, Chen R, Gabriel S, et al. Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. Kidney Int Suppl 2005;67(Suppl. 93):S52-S54.
217. Hobbs H, Stevens P, Klebe B, Irving J, Cooley R, O'Donoghue D, et al. Referral patterns to renal services: what has changed in the past 4 years? Nephrol Dial Transplant 2009;1-8.
218. Philips LA, Donovan KL, Philips AO. Renal quality outcomes framework and eGFR: impact on secondary care. QJM 2009;102:415-23.
219. Krol E, Rutkowski B, Czarniak P, Kraszewska E, Lizakowski S, Szubert R, et al. Early detection of chronic kidney disease: Results of the PolNef Study. Am J Nephrol 2009;29:264-73.
220. Vassalotti JA, Gracz-Weinstein L, Gannon MR, Brown WW. Targeted screening and treatment of chronic kidney disease. Lessons learned from the Kidney Early Evaluation Program. Dis Manag Health Outcomes 2006;14:341-52.
221. Blackburn RC, Parke CL, Sharma P, McCullough K, Black C. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1-3) non-diabetic chronic kidney disease (Protocol). The Cochrane Database of Systematic Reviews 2009.
222. Anees M, Mumtaz A, Nazir M, Ibrahim M, Rizwan SM, Kausar T. Referral pattern fof hemodialysis patients to nephrologists. J Coll Physicians Surg Pak 2007;17:671-4.
223. Arora P, Obrador GT, Ruthazer R, Kausz AT, Meyer KB, Jenuleson CS, et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol 1999;10:1281-6.
224. Avorn J, Bohn RL, Levy E, Levin R, Owen WF Jr, Winkelmayer WC, et al. Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med 2002;162:2002-6.
225. Baker A, McMahon A, Cockfield SM. Delayed referral of patients with chronic kidney disease is an independent risk factor for mortality. J Am Soc Nephrol 2003;14:813a.
226. Barril G, Sanz P, Bardon E, Andrino T, Cigarran S, Selgas R. Earliest referral to advanced chronic kidney disease unit (ACKDU) could prevent renal osteodystrophy (ROD). J Am Soc Nephrol 2002;13:672A-3A.
227. Brown WW, Collins A, Chen SC, King K, Molony D, Gannon MR, et al. Identification of persons at high risk for kidney disease via targeted screening: the NKF Kidney Early Evaluation Program. Kidney Int Suppl 2003;63:S50-S55.
228. Burton CJ, Feest TG. Does referral to a renal clinic slow the progression of diabetic nephropathy? An audit of 100 consecutive referrals. Kidney Int 1999;55:2110.
229. Caskey FJ, Wordsworth S, Ben T, de Charro FT, Delcroix C, Dobronravov V, et al. Early referral and planned initiation of dialysis: what impact on quality of life? Nephrol Dial Transplant 2003;18:1330-8.
230. Cass A, Cunningham J, Arnold PC, Snelling P, Wang Z, Hoy W. Delayed referral to a nephrologist: outcomes among patients who survive at least one year on dialysis. Med J Aust 2002;177:135-8.
231. Chan MR, Dall AT, Fletcher KE, Lu N, Trivedi H. Outcomes in patients with chronic kidney disease referred late to nephrologists: A meta-analysis. Am J Med 2007;120:1063-70.
232. Chandna SM, Schulz J, Lawrence C, Greenwood RN, Farrington K. Is there a rationale for rationing chronic dialysis? A hospital based cohort study of factors affecting survival and morbidity. BMJ 1999;318:217-23.
233. Curtis BM, Barrett BJ, Djurdjev O, Singer J, Levin A. Evaluation and treatment of CKD patients before and at their first nephrologist encounter in Canada. Am J Kidney Dis 2007;50:733-42.
234. Dautlich J, Worth D, Strang J. Chronic renal insufficiency: unmet need for referral to a renal physician. Kidney Int 1999;55:2568.
235. Dogan E, Erkoc R, Sayarlioglu H, Durmus A, Topal C. Effects of late referral to a nephrologist in patients with chronic renal failure. Nephrology 2005;10:516-19.
236. Ellis PA, Reddy V, Bari N, Cairns HS. Late referral of end-stage renal failure. QJM 1998;91:727-32.
237. Fan SL, Marsh FP, Raftery MJ, Yaqoob MM. Do patients referred late for peritoneal dialysis do badly? Perit Dial Int 2002;22:630-2.
238. Fox CH, Brooks A, Zayas LE, McClellan W, Murray B. Primary care physicians' knowledge and practice patterns in the treatment of chronic kidney disease: An Upstate New York Practice-based Research Network (UNYNET) study. J Am Board Fam Med 2006;19:54-61.
239. Goransson LG, Bergrem H. Consequences of late referral of patients with end-stage renal disease. J Int Med 2001;250:154-9.
240. Harris SAC, Brown EA, Lamping DL, Constantinovici N, Henderson L, Roderick P, et al. Effect of late referral to a nephrologist on quality of life of elderly dialysis patients. Kidney Int 1999;55:2115.
241. Hyder M, Manchester G, Fan PY. Referral patterns for renal insufficiency. J Gen Intern Med 2000;15:123.
242. Innes A, Rowe PA, Burden RP, Morgan AG. Early deaths on renal replacement therapy: the need for early nephrological referral. Nephrol Dial Transplant 1992;7:467-71.
243. Iseki K. Analysis of referral pattern and survival in chronic dialysis patients in Okinawa, Japan (1993-1997). Clin Exp Nephrol 2002;6:43-8.
244. Ismail N, Neyra R, Hakim R. The medical and economical advantages of early referral of chronic renal failure patients to renal specialists. Nephrol Dial Transplant 1998;13:246-50.
245. Jungers P, Zingraff J, Page B, Albouze G, Hannedouche T, Man NK. Detrimental effects of late referral in patients with chronic renal failure: a case-control study. Kidney Int Suppl 1993;41:S170-S173.
246. Jungers P, Zingraff J, Albouze G, Chauveau P, Page B, Hannedouche T, et al. Late referral to maintenance dialysis: detrimental consequences. Nephrol Dial Transplant 1993;8:1089-93.
247. Jungers P, Skhiri H, Giatras I, Muller S, Fumeron C, Touam M, et al. Beneficial effects of early nephrological referral of chronic renal failure patients. J Am Soc Nephrol 1997;8:A0663.
248. Kazmi W, Khan SS. Late referral and it's association with probability or being wait-listed for cadaveric kidney transplant. Am J Kidney Dis 2002;39:A20.
249. Kazmi WH, Obrador GT, Khan SS, Pereira BJ, Kausz AT. Late nephrology referral and mortality among patients with end-stage renal disease: a propensity score analysis. Nephrol Dial Transplant 2004;19:1808-14.
250. Klebe B, Irving J, Stevens PE, O'Donoghue DJ, de LS, Cooley R, et al. The cost of implementing UK guidelines for the management of chronic kidney disease. Nephrol Dial Transplant 2007;22:2504-12.
251. Lhotta K, Zoebl M, Mayer G, Kronenberg F. Late referral defined by renal function: association with morbidity and mortality. J Nephrol 2003;16:855-61.
252. Lin CL, Wu MS, Hsu PY, Huang CC. Improvement of clinical outcome by early nephrology referral in type II diabetics on hemodialysis. Ren Fail 2003;25:455-64.
253. Lin CL, Chuang FR, Wu CF, Yang CT. Early referral as an independent predictor of clinical outcome in end-stage renal disease on hemodialysis and continuous ambulatory peritoneal dialysis. Ren Fail 2004;26:531-7.
254. Locatelli F, Vecchio LD, Pozzoni P. The importance of early detection of chronic kidney disease. Nephrol Dial Transplant 2002;17(Suppl. 11):2-7.
255. London R, Solis A, Goldberg GA, Wade S, Chan WW. Examination of resource use and clinical interventions associated with chronic kidney disease in a managed care population. J Manag Care Pharm 2003;9:248-55.
256. Lusenti T, Rustichelli R, Cardarelli F, Gregorini M, Borgatti P, Giacometti P, et al. The early referral to nephrologist preserves renal function in patients with chronic renal failure associated to renal artery stenosis. Nephrol Dial Transplant 2006;21:382.
257. Mendelssohn DC, Barrett BJ, Brownscombe LM, Ethier J, Greenberg DE, Kanani SD, et al. Elevated levels of serum creatinine: recommendations for management and referral. CMAJ 1999;161:413-17.
258. Ohmit SE, Flack JM, Peters RM, Brown WW, Grimm R. Longitudinal Study of the National Kidney Foundation's (NKF) Kidney Early Evaluation Program (KEEP). J Am Soc Nephrol 2003;14:S117-S121.
259. Paris V, Ballerini L. Patient flow analysis and referrals: how 1,137 ESRD patients started dialysis during 1998-1999. EDTNA ERCA J 2002;169:160-63.
260. Rao M, Lindberg J, Port FK, Lin F, Kausz AT, Pereira BJG, et al. Patterns of referral to the nephrologist for chronic kidney disease care - Results from the STRIDE registry. J Am Soc Nephrol 2002;13:253a.
261. Rasgon SA, Yeoh HH, Kujubu D, Bhalotra S, Tompkins CP. Importance of early referral to the nephrologist. J Am Soc Nephrol 2003;14:815A.
262. Ratcliffe PJ, Phillips RE, Oliver DO. Late referral for maintenance dialysis. Br Med J (Clin Res Ed) 1984;288:441-3.
263. Ravani P, Marinangeli G, Stacchiotti L, Malberti F. Structured pre-dialysis programs: more than just timely referral? J Nephrol 2003;16:862-9.
264. Roderick P, Drey N, Webster P, Blakely S, Mason J, Tomson C. Late referral for renal replacement therapy in the South West Region - how common is it and what are its determinants and sequelae? Kidney Int 1999;55:2588-9.
265. Roderick P, Jones C, Tomson C, Mason J. Late referral for dialysis: improving the management of chronic renal disease. QJM 2002;95:363-70.
266. Roubicek C, Brunet P, Huiart L, Thirion X, Leonetti F, Dussol B, et al. Timing of nephrology referral: influence on mortality and morbidity. Am J Kidney Dis 2000;36:35-41.
267. Rutherford PA, Rutherford S, Drew PJT. Adverse effects of late referral for nephrological opinion. Kidney Int 1997;52:1128.
268. Schmidt RJ, Domico JR, Sorkin MI, Hobbs G. Early referral and its impact on emergent first dialyses, health care costs, and outcome. Am J Kidney Dis 1998;32:278-83.
269. Schwenger V, Morath C, Hofmann A, Hoffmann O, Zeier M, Ritz E. Late referral - a major cause of poor outcome in the very elderly dialysis patient. Nephrol Dial Transplant 2006;21:962-7.
270. Sesso R, Belasco AG. Late diagnosis of chronic renal failure and mortality on maintenance dialysis. Nephrol Dial Transplant 1996;11:2417-20.
271. Shin SJ, Kim HW, Chung S, Chung HW, Lee SJ, Kim YS, et al. Late referral to a nephrologist increases the risk of uremia-related cardiac hypertrophy in patients on hemodialysis. Nephron 2007;107:c139-c146.
272. Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. Am J Kidney Dis 2003;41:310-18.
273. Stoves J, Bartlett CN, Newstead CG. Specialist follow up of patients before end stage renal failure and its relationship to survival on dialysis. Postgrad Med J 2001;77:586-8.
274. Thomas MC. Early referral of patients with pre-endstage kidney disease. Nephrology 2007;12:S41-S43.
275. Wavamunno MD, Harris DC. The need for early nephrology referral. Kidney Int Suppl 2005;94:S128-S132.
276. White CA, Pilkey RM, Lam M, Holland DC. Predialysis clinic attendance improves quality of life among hemodialysis patients. BMC Nephrol 2002;3:3.
277. Winkelmayer WC, Owen WF Jr, Levin R, Avorn J. A propensity analysis of late versus early nephrologist referral and mortality on dialysis. J Am Soc Nephrol 2003;14:486-92.
278. Wu M-S. Improvement in clinical outcome by early nephrology referral in type II diabetics on maintenance peritoneal dialysis. Perit Dial Int 2003;23:39-45.
279. Agency for Healthcare Research and Quality. Late referral to specialty care contributes to poor outcomes among patients with kidney failure. Res Activities 2002;4-5.
280. Agency for Healthcare Research and Quality. Early referral of patients with chronic kidney disease reduces complications and mortality. Res Activities 2005;15.
281. Agency for Healthcare Research and Quality. Studies show that early nephrologist referral and frequent visits improve survival among ESRD patients. Res Activities 2002;17-18.
282. Altman JJ, Elian N, Grun S, Gerard HG, Feldman S. The outcome of advanced chronic nephropathy in type 1 and type 2 diabetic and non-diabetic patients: a prospective study. Diabetes Metab 1999;25:144-9.
283. Boes E, Fliser D, Ritz E, Konig P, Lhotta K, Mann JF, et al. Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2006;17:528-36.
284. Bruno G, Biggeri A, Merletti F. Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. Diabetes Care 2003;26:2353-8.
285. Busch M, Franke S, Wolf G, Brandstadt A, Ott U, Gerth J, et al. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am J Kidney Dis 2006;48:571-9.
286. Chandie Shaw PK, Baboe F, van Es LA, van der Vijver JC, van de Ree MA, de Jonge N, et al. SouthAsian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch-European diabetic patients. Diabetes Care 2006;29:1383-5.
287. Chauveau P, Combe C, Rigalleau V, Vendrely B, Aparicio M. Restricted protein diet is associated with decrease in proteinuria: consequences on the progression of renal failure. J Ren Nutr 2007;17:250-7.
288. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007;50:239-47.
289. Christensen PK, Rossing P, Nielsen FS, Parving HH. Natural course of kidney function in Type 2 diabetic patients with diabetic nephropathy. Diabetic Med 1999;16:388-94.
290. Costacou T, Ellis D, Fried L, Orchard TJ. Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: a cohort study. Am J Kidney Dis 2007;50:721-32.
291. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007;13:599-608.
292. Dean BB, Dylan M, Gano A, Jr., Knight K, Ofman JJ, Levine BS. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005;21:981-7.
293. Drummond K, Mauer M, International Diabetic Nephropathy Study G. The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 2002;51:1580-7.
294. Earle KK, Porter KA, Ostberg J, Yudkin JS. Variation in the progression of diabetic nephropathy according to racial origin. Nephrol Dial Transplant 2001;16:286-90.
295. Edwards MS, Wilson DB, Craven TE, Stafford J, Fried LF, Wong TY, et al. Associations between retinal microvascular abnormalities and declining renal function in the elderly population: the Cardiovascular Health Study. Am J Kidney Dis 2005;46:214-24.
296. El Kossi MM, Ibrahim A, Lock TJ, el Nahas AM. Impact of cardiac transplantation on kidney function: a single- center experience. Transplant Proc 2003;35:1527-31.
297. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005;16:2456-61.
298. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007;18:2600-8.
299. Fried L, Solomon C, Shlipak M. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 2004;15:3184-91.
300. Hadjadj S, Duly-Bouhanick B, Bekherraz A, Bridoux F, Gallois Y, Mauco G, et al. Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab 2004;30:43-51.
301. Hebert LA, Greene T, Levey A, Falkenhain ME, Klahr S. High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis 2003;41:962-71.
302. Henry RMA, Kostense PJ, Bos G. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn study. Kidney Int 2002;62:1402-7.
303. Hovind P, Rossing P, Tarnow L, Parving HH. Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2003;26:911-16.
304. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 2001;60:277-83.
305. Hoy WE, Kondalsamy-Chennakesavan S, McDonald S, Wang Z. Renal disease, the metabolic syndrome, and cardiovascular disease. Ethn Dis 2006;16(Suppl. 2):46-51.
306. Hsu CCC, Bray MS, Kao WHL, Pankow JS, Boerwinkle E, Coresh J. Genetic variation of the renin-angiotensin system and chronic kidney disease progression in black individuals in the atherosclerosis risk in communities study. J Am Soc Nephrol 2006;17:504-12.
307. Imbasciati E, Gregorini G, Cabiddu G, Gammaro L, Ambroso G, Del Giudice A, et al. Pregnancy in CKD stages 3 to 5: fetal and maternal outcomes. Am J Kidney Dis 2007;49:753-62.
308. Iseki K, Ikemiya Y, Iseki C, Takishita S. Prevalence of high fasting plasma glucose and risk of developing end-stage renal disease in screened subjects in Okinawa, Japan. Clin Exp Nephrol 2004;8:250-6.
309. Jacobsen P, Rossing K, Tarnow L, Rossing P, Mallet C, Poirier O, et al. Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int Suppl 1999;71:S101-S105.
310. Jacobsen P, Rossing P, Tarnow L, Hovind P, Parving HH. Birth weight--a risk factor for progression in diabetic nephropathy? Journal of Internal Medicine 2003;253:343-50.
311. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, et al. Proteinuria as a modifiable risk factor for the progression of nondiabetic renal disease. Kidney Int 2001;60:1131-40.
312. Jafar TH, Schmid CH, Stark PC, Toto R, Remuzzi G, Ruggenenti P, et al. The rate of progression of renal disease may not be slower in women compared with men: a patient-level metaanalysis. Nephrol Dial Transplant 2003;18:2047-53.
313. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Int Med 2003;139:244-52, I36.
314. Jovanovic DB, Djukanovic L. Analysis of factors influencing chronic renal failure progression. Ren Fail 1999;21:177-87.
315. Jude EB, Anderson SG, Cruickshank JK. Natural history and prognostic factors of diabetic nephropathy in type 2 diabetes. J Assoc Physicians 2002;95:371-7.
316. Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A metaanalysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 1998;31:954-61.
317. Kim SB, Kwon S, Lee SK, Park JS. Association of atherosclerotic coronary artery disease and pulse pressure with renal disease progression. Ren Fail 2003;25:1019-27.
318. Kohli HS, Bhat A, Aravindan, Sud K, Jha V, Gupta KL, et al. Spectrum of renal failure in elderly patients. Int Urol Nephrol 2006;38:759-65.
319. Kristjansson K, Ljungman S, Bengtsson C, Bjorkelund C, Sigurdsson JA. Microproteinuria and long-term prognosis with respect to renal function and survival in normotensive and hypertensive women: A 24-year follow-up of a representative population sample of women in Gothenburg, Sweden. Scand J Urol Nephrol 2001;35:63-70.
320. Kronborg J, Solbu M, Njolstad I, Toft I, Eriksen BO. Predictors of change in estimated GFR: a population-based 7-year follow-up from the Tromso study. Nephrol Dial Transplant 2008;23:2818-26.
321. Larsson A, Helmersson J, Hansson L-O, Basu S. Increased serum cystatin C is associated with increased mortality in elderly men. Scand J Clin Lab Invest 2005;65:301-5.
322. Leeder SR, Mitchell P, Liew G, Rochtchina E, Smith W, Wang JJ. Low hemoglobin, chronic kidney disease, and risk for coronary heart disease-related death: The Blue Mountains Eye Study. J Am Soc Nephrol 2006;17:279-84.
323. Lerma EV. ACE inhibitors, but not angiotensin II receptor antagonists, reduce all cause mortality in diabetic nephropathy. Evid Based Med 2005;10:77.
324. Locatelli F, Del Vecchio L, Andrulli S, Marai P, Tentori F. The role of underlying nephropathy in the progression of renal disease. Kidney Int Suppl 2000;75:S49-S55.
325. Mann JF, Gerstein HC, Yi QL, Franke J, Lonn EM, Hoogwerf BJ, et al. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis 2003;42:936-42.
326. Marcotte L, Godwin M. Natural history of elevated creatinine levels. Can Fam Physician 2006;52:1264-5.
327. Massy ZA, Nguyen Khoa T, Lacour B, scampsLatscha B, Man NK, Jungers P. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant 1999;14:2392-7.
328. McClellan WM, Langston RD, Presley R. Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 2004;15:1912-9.
329. Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 2001;16:2207-13.
330. Merkin SS, Coresh J, ez Roux AV, Taylor HA, Powe NR. Area socioeconomic status and progressive CKD: The atherosclerosis risk in communities (ARIC) study. Am J Kidney Dis 2005;46:203-13.
331. Middleton RJ, Foley RN, Hegarty J, Cheung CM, McElduff P, Gibson JM, et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant 2006;21:88-92.
332. Morita S, Fukuhara S, Akizawa T, Asano Y, Koshikawa S, Koide K, et al. Prognostic factors for a composite end-point of renal outcomes in patients with chronic kidney disease. Ther Apher Dial 2006;10:72-7.
333. Muhlhauser I, Sawicki PT, Blank M, Overmann H, Bender R, Berger M. Prognosis of persons with type 1 diabetes on intensified insulin therapy in relation to nephropathy. J Int Med 2000;248:333-41.
334. Neild GH, Thomson G, Nitsch D, Woolfson RG, Connolly JO, Woodhouse CR. Renal outcome in adults with renal insufficiency and irregular asymmetric kidneys. BMC Nephrol 2004;5:12.
335. Orth SR, Hallan SI. Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients--absence of evidence or evidence of absence? Clin J Am Soc Nephrol 2008;3:226-36.
336. Perlman RL, Kiser M, Finkelstein F, Eisele G, Roys E, Liu L, et al. The longitudinal chronic kidney disease study: a prospective cohort study of predialysis renal failure. Semin Dial 2003;16:418-23.
337. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 1998;53:1209-16.
338. Rigalleau V, Lasseur C, Raffaitin C, Perlemoine C, Barthe N, Chauveau P, et al. Prediction of glomerular filtration rate decline in diabetic subjects with impaired renal function. Nephrol Dial Transplant 2007;22:959-60.
339. Rottey S, Vanholder R, De Schoenmakere G, Lameire N. Progression of renal failure in patients with compromised renal function is not always present: evaluation of underlying disease. Clin Nephrol 2000;54:1-10.
340. Samuelsson O, Attman PO. Is smoking a risk factor for progression of chronic renal failure? Kidney Int 2000;58:2597.
341. Sesso R, Prado F, Vicioso B, Ramos LR. Prospective study of progression of kidney dysfunction in community-dwelling older adults. Nephrology 2008;13:99-103.
342. Song KH, Ko SH, Kim HW, Ahn YB, Lee JM, Son HS, et al. Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria. Diabetes Care 2005;28:1718-23.
343. Stam F, Van GC, Decker A. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: The Hoorn study. J Am Soc Nephrol 2006;17:537-45.
344. Stojceva-Taneva O, Polenakovic M, Grozdanovski R, Sikole A. Lipids, protein intake, and progression of diabetic nephropathy. Nephrol Dial Transplant 2001;16:90-1.
345. Thomas MC, Rosengard-Barlund M, Mills V, Ronnback M, Thomas S, Forsblom C, et al. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 2006;29:317-22.
346. Ueda H, Ishimura E, Shoji T, Emoto M, Morioka T, Matsumoto N, et al. Factors affecting progression of renal failure in patients with type 2 diabetes. Diabetes Care 2003;26:1530-4.
347. Wang MC, Tsai WC, Chen JY, Huang JJ. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005;45:494-501.
348. Wasse H, McClellan W. Risk for progression to ESRD: Further evidence from population-based studies. J Am Soc Nephrol 2006;17:2092-3.
349. Wright JR, Shurrab AE, Cheung C, Waldek S, O'Donoghue DJ, Foley RN, et al. A prospective study of the determinants of renal functional outcome and mortality in atherosclerotic renovascular disease. Am J Kidney Dis 2002;39:1153-61.
350. Levin A. Consequences of late referral on patient outcomes. Nephrol Dial Transplant 2000;15(Suppl. 3):8-13.
351. Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis 1998;31:398-417.
352. Avorn J, Winkelmayer WC, Bohn RL, Levin R, Glynn RJ, Levy E, et al. Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. J Clin Epidemiol 2002;55:711-16.
353. Navaneethan SD, Aloudat S, Singh S. A systematic review of patient and health system characteristics associated with late referral in chronic kidney disease. BMC Nephrol 2008;9:3.
354. Wauters JP, Lameire N, Davison A, Ritz E. Why patients with progressing kidney disease are referred late to the nephrologist: on causes and proposals for improvement. Nephrol Dial Transplant 2005;20:490-6.
355. Winkelmayer WC, Glynn RJ, Levin R, Owen WF, Jr., Avorn J. Determinants of delayed nephrologist referral in patients with chronic kidney disease. Am J Kidney Dis 2001;38:1178-84.
356. Ifudu O, Dawood M, Iofel Y, Valcourt JS, Friedman EA. Delayed referral of black, Hispanic, and older patients with chronic renal failure. Am J Kidney Dis 1999;33:728-33.
357. Navaneethan SD, Nigwekar S, Sengodan M, Anand E, Kadam S, Jeevanantham V, et al. Referral to nephrologists for chronic kidney disease care: is non-diabetic kidney disease ignored? Nephron 2007;106:c113-c118.
358. Mendelssohn DC, Kua BT, Singer PA. Referral for dialysis in Ontario. Arch Intern Med 1995;155:2473-8.
359. Wauters JP, Bosson JL, Forneris G, Turc-Baron C, Golshayan D, Paternoster G, et al. Patient referral is influenced by dialysis centre structure in the Diamant Alpin Dialysis cohort study. Nephrol Dial Transplant 2004;19:2341-6.
360. Steel J, Ellis P. Do demographic variables affect the timing of referral to the nephrologist? EDTNA ERCA J 2002;28:185-7.
361. Montgomery AJ, McGee HM, Shannon W, Donohoe J. Factors influencing general practitioner referral of patients developing end-stage renal failure: a standardised case-analysis study. BMC Health Serv Res 2006;6:114.
362. Cass A, Cunningham J, Snelling P, Ayanian JZ. Late referral to a nephrologist reduces access to renal transplantation. Am J Kidney Dis 2003;42:1043-9.
363. Obialo CI, Ofili EO, Quarshie A, Martin PC. Ultralate referral and presentation for renal replacement therapy socioeconomic implications. Am J Kidney Dis 2005;46:881-6.
364. Kee F, Reaney E, Savage G, O'Reilly D, Patterson C, Maxwell P, et al. Are gatekeepers to renal services referring patients equitably? J Health Serv Res Pol 2007;12:36-41.
365. Sprangers B, Evenepoel P, Vanrenterghem Y. Late referral of patients with chronic kidney disease: no time to waste. Mayo Clin Proc 2006;81:1487-94.
366. Cass A, Cunningham J, Snelling P, Wang Z, Hoy W. Urban disadvantage and delayed nephrology referral in Australia. Health Place 2003;9:175-82.
367. Boulware LE, Troll MU, Jaar BG, Myers DI, Powe NR. Identification and Referral of Patients With Progressive CKD: A National Study. Am J Kidney Dis 2006;48:192-204.
368. Parry RG, Crowe A, Stevens JM, Mason JC, Roderick P. Referral of elderly patients with severe renal failure: questionnaire survey of physicians. BMJ 1996;313:466.
369. Campbell JD. The timing of referral of patients with end-stage renal disease. Dial Transplant 1989;18:660-86.